Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma

Background: Immunotherapy has drastically changed the outlook for melanoma patients over the past decade. Specifically, the dual blockade of immune checkpoints using ipilimumab and nivolumab has shown unprecedented response rates and survival outcomes. This immense achievement, though, is at the cos...

Descripción completa

Detalles Bibliográficos
Autores principales: Asher, Nethanel, Ben-Betzalel, Guy, Lev-Ari, Shaked, Shapira-Frommer, Ronnie, Steinberg-Silman, Yael, Gochman, Neta, Schachter, Jacob, Meirson, Tomer, Markel, Gal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464656/
https://www.ncbi.nlm.nih.gov/pubmed/32824780
http://dx.doi.org/10.3390/cancers12082329

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464656/
https://www.ncbi.nlm.nih.gov/pubmed/32824780
http://dx.doi.org/10.3390/cancers12082329

Ejemplares similares